Market Pulse: Tech sector drifted into red territory, with chipmakers stumbling under the weight of fresh tariff news and investor jitters.
Key Movers: “OpenAI has committed billions to recent chip deals. Some big names have been left out” (CNBC) grabbed headlines, while Corcept and Soleno plunged on FDA setbacks.
Macro & Politics: Washington’s surprise 25% tariff on AI chip imports roiled trading floors and sparked fresh scrutiny of supply chains.
What’s Next: Eyes on early open as traders digest tariff impacts and any FDA commentary on relacorilant could flip biotech sentiment.
📈 Breaking Financial News
OpenAI has committed billions to recent chip deals. Some big names have been left out
OpenAI has inked multibillion-dollar deals with AI chipmakers including Nvidia, AMD, Broadcom and Cerebras.
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman
Investors who lost money in CORT after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% — Hagens Berman
Investors who lost money in SLNO after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
AI Diagnostics: The End of the High-Cost Imaging Era
Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER, British Columbia, Jan. 16, 2026 — The AI medical imaging market is entering a phase of explosive 25.8% annual growth through 2034.
AI Diagnostics: The End of the High-Cost Imaging Era
Issued on behalf of VentriPoint Diagnostics Ltd. Issued on behalf of VentriPoint Diagnostics Ltd.
The Liquidity Engine Powering Crypto's Comeback The post-tariff crypto boom is u
Institutional capital is flooding in while most investors remain completely unaware – creating what could be the buying opportunity of a lifetime. Exposed: Crypto's liquidity backbone set for massive gains – get all details for just $3!
🔍 Market Analysis & Insights
Web3 revenue shifts from blockchains to wallets and DeFi apps
A growing amount of the blockchain industry’s fees are captured by DeFi protocols rather than the underlying networks, signaling a potential investor shift to front-end facing applications.
Vision Care Market Size to Surpass USD 169.38 Billion by 2032, Driven by Rising Vision Disorders | Coherent Market Insights
Burlingame, CA, Jan. 16, 2026 — The Global Vision Care Market is estimated to be valued at USD 104.11 Bn in 2025 and is expected to reach USD 169.38 Bn by 2032, exhibiting a CAGR of 7.2% from 2025 to 2032.
Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market Insights
Pan-genomic And Multi-gene Panel Testing Market size was valued at US$ 8,907.34 Million in 2024, expanding at a CAGR of 12.04% from 2025 to 2032.
Bitcoin – Identifying the risks to BTC’s leverage-driven price rally
Bitcoin's latest rally has been more unusual than usual recently.
Strongest Adderall Alternative 2026: NeuroXen Report Maps OTC “Adderall Alternative” Search Behavior and a 5-Point Verification Framework
Strongest Adderall Alternative 2026 consumer analysis: NeuroXen report maps OTC nootropic options and 5-point supplement verification framework.
One specific coin aligns perfectly with Trump's regulatory reforms and vision for America's financial dominance in the digital age. The best part? This platform is already processing more transactions than all its competitors combined, yet remarkably remains under most investors' radar. Get the name of the ideal crypto for Trump's presidency for just $3 before his policies drive prices higher.
Get the name of the ideal crypto for Trump's presidency for just $3 before his policies drive prices higher.
💰 Investment Opportunities
Hemophagocytic Lymphohistiocytosis Market Poised for Phenomenal Expansion in the US at a CAGR of 24.5% During the Forecast Period (2025-2034) | DelveInsight
The hemophagocytic lymphohistiocytosis market is expected to increase due to the launch of emerging therapies, such as plonmarlimab, ELA026, MAS825, tadekinig alfa, and others.
Strongest Phentermine Alternatives 2026: What OTC Options Actually Exist? Phen24 Consumer Search Analysis and 7-Point Verification Framework
Strongest Phentermine Alternatives 2026: Phen24 consumer search analysis, OTC vs prescription context, and 7-point verification framework.
5 AI Chip Stocks Most Exposed to Trump’s New 25% Tariff
Trump’s 25% tariff on AI chips landed the same day Taiwan Semiconductor Manufacturing Company (TSMC) posted blowout earnings and dismissed AI bubble fears.
ETH’s next stop could be $4.1K, but this must happen first
An emerging ETH futures trend is predicting an Ether price rally to $4,100, but other data says the altcoin is overdue for a slight correction.
Metadata Mastery Shatters Delays, Accelerates Therapies to Patients Globally
Chitiz Tayal's metadata tool transforms vendor onboarding in pharmaceutical campaigns, reducing setup times from months to days.
The Elon Musk “Mystery Metal” That Could Break China's Grip Trump called America's rare-ea
quietly engineered by Elon Musk… could end that crisis forever. And one tiny company is sitting at the center of it all. Musk is expected to make an announcement any day now. See more about this secret project here.
Market Commentary
Everyone’s obsessing over Nvidia and AMD dominance in the chip race, but they’re missing a bigger battleground: the smaller AI silicon specialists cut out of OpenAI’s megadeals. If you think incumbents have unassailable moats, think again. Sources like CNBC’s “OpenAI has committed billions to recent chip deals. Some big names have been left out” show the real volatility lies with emerging players. Damn, the tariff bomb on AI chips adds another layer, shifting production plans overnight.
Meanwhile, biotech boards are bleeding after “Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50%” (GlobeNewswire) and Soleno’s slow VYKAT XR start. But here’s the twist: as regulatory red tape throttles drug launches, we’re seeing capital tilt toward DeFi builders—Cointelegraph’s “Web3 revenue shifts from blockchains to wallets and DeFi apps” highlights that pivot. It’s ironic: federal caution in healthcare is fueling financial innovation on-chain.
My takeaway? Rotate out of biotech stories mired in FDA purgatory into AI and DeFi plays that can sidestep tariffs and red tape. Scope out AI chip names with domestic partnerships, and monitor DeFi protocols clawing fee share from legacy blockchains. Don’t just chase headlines—trail the money and stay a step ahead of the herd.